1. Lisette Pregelj is a postdoctoral research fellow in the Business School, University of Queensland, in Brisbane, Australia.
2. Thomas J. Hwang is a researcher in the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, in Boston, Massachusetts.
3. Damian C. Hine () is an associate professor of innovation and director of the Asia Pacific Enterprise Initiative in the Business Economics and Law Faculty, University of Queensland.
4. Evan B. Siegel is CEO of Ground Zero Pharmaceuticals, Inc., in Irvine, California, and an adjunct professor in the School of Chemistry and Molecular Biosciences, University of Queensland.
5. Ross T. Barnard is a professor of biotechnology and director of the Biotechnology Program, School of Chemistry and Molecular Biosciences, and ARC Training Centre for Biopharmaceutical Innovation, University of Queensland.
6. Jonathan J. Darrow is a faculty member in the Program on Regulation, Therapeutics, and Law in the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School.
7. Aaron S. Kesselheim is an associate professor of medicine at Harvard Medical School and director of the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School.